Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arana Therapeutics VP Cliff Holloway On Building A U.S.-Style Biotech In Australia: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Arana Therapeutics announced April 24 a co-development deal with Japanese biotech company Kyowa Hakko Kogyo to develop anticancer drug ART104 for colorectal cancer. Under the deal Arana, based in Sydney, Australia, receives an up-front payment of $4 million and additional milestones of up to $4 million. The companies will share equal ownership and development costs; Kyowa Hakko has an option to develop and commercialize the product in some Asian markets, including China, Japan, South Korea and Taiwan.

You may also be interested in...



Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup

Stranded New Zealand Pig Herd Could Offer Better Treatments For Diabetes

Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup

Stranded New Zealand Pig Herd Could Offer Better Treatments For Diabetes

Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy

TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23

Related Content

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel